2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/1855-ogyi8eh4.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/25a3ozcrvi1ff.js","/_next/static/immutable/chunks/2r4wx50nvjh_4.js","/_next/static/immutable/chunks/23fsw06hsi5b1.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/3ezsiz-7shkna.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2lxntcm3pd1_h.js","/_next/static/immutable/chunks/00dgco8irq3jw.js","/_next/static/immutable/chunks/00nwe-kq0rboc.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T6f5,Patients with stage II/III human epidermal growth factor receptor 2 (HER2)-positive or triple-negative breast cancer (TNBC) frequently receive neoadjuvant therapy (NAT). Although pathologic complete response (pCR) correlates with improved outcomes, many non-pCR patients have long-term survival. Circulating tumor-DNA (ctDNA) minimal residual disease (MRD) assessment may provide additional or superior risk stratification. Pathologic Response Evaluation and Detection in Circulating Tumor-DNA is a prospective, multicenter study evaluating ctDNA as a biomarker of treatment response using a tumor-informed, ultrasensitive (<100 parts per million) assay. The primary objective was to determine whether the negative predictive value (NPV) of post-NAT ctDNA for pCR was ≥90%. A prespecified secondary objective for the TNBC cohort was to assess associations between ctDNA and 5-year invasive disease-free survival (IDFS). ctDNA was evaluated at baseline, after NAT before surgery, and after surgery. Of 227 enrolled patients, 220 were evaluable for pCR (48% HER2-positive; 52% TNBC) and 91 patients (41%) had pCR. The primary objective was not met. Although all patients with pCR were ctDNA-negative after NAT, 40% of non-pCR patients were also ctDNA-negative (NPV, 60% [95% CI, 0.50 to 0.69]). However, the prespecified secondary objective was met. Detectable ctDNA after NAT was prognostic for recurrence (hazard ratio [HR], 8.9 [95% CI, 2.4 to 33]; In HER2-positive breast cancer and TNBC, ctDNA after NAT does not discriminate pCR from non-pCR. However, ctDNA provides markedly superior prognostic stratification, identifying patients with exceptional outcomes and those at extreme risk. These findings support ctDNA-guided therapeutic de-escalation and escalation strategies.31:Tb03, PURPOSE Patients with stage II/III human epidermal growth factor receptor 2 (HER2)–positive or triple-negative breast cancer (TNBC) frequently receive neoadjuvant therapy (NAT). Although pathologic complete response (pCR) correlates with improved outcomes, many non-pCR patients have long-term survival. Circulating tumor-DNA (ctDNA) minimal residual disease (MRD) assessment may provide additional or superior risk stratification. METHODS Pathologic Response Evaluation and Detection in Circulating Tumor-DNA is a prospective, multicenter study evaluating ctDNA as a biomarker of treatment response using a tumor-informed, ultrasensitive (<100 parts per million) assay. The primary objective was to determine whether the negative predictive value (NPV) of post-NAT ctDNA for pCR was ≥90%. A prespecified secondary objective for the TNBC cohort was to assess associations between ctDNA and 5-year invasive disease-free survival (IDFS). ctDNA was evaluated at baseline, after NAT before surgery, and after surgery. RESULTS Of 227 enrolled patients, 220 were evaluable for pCR (48% HER2-positive; 52% TNBC) and 91 patients (41%) had pCR. The primary objective was not met. Although all patients with pCR were ctDNA-negative after NAT, 40% of non-pCR patients were also ctDNA-negative (NPV, 60% [95% CI, 0.50 to 0.69]). However, the prespecified secondary objective was met. Detectable ctDNA after NAT was prognostic for recurrence (hazard ratio [HR], 8.9 [95% CI, 2.4 to 33]; P = .001), independent of pCR. Additionally, detectable ctDNA after surgery identified patients at extremely high recurrence risk (HR, 128 [95% CI, 15 to 1,083]; P < .001), while ctDNA-negative patients after surgery had 94% 5-year IDFS. CONCLUSION In HER2-positive breast cancer and TNBC, ctDNA after NAT does not discriminate pCR from non-pCR. However, ctDNA provides markedly superior prognostic stratification, identifying patients with exceptional outcomes and those at extreme risk. These findings support ctDNA-guided therapeutic de-escalation and escalation strategies. 32:T406,Among 558 patients, median progression-free survival was 9.7 months (95% confidence interval [CI], 8.1 to 11.1) with sacituzumab govitecan and 6.9 months (95% CI, 5.6 to 8.2) with chemotherapy (stratified hazard ratio for disease progression or death, 0.62; 95% CI, 0.50 to 0.77; P<0.001). An objective response was confirmed in 48% of patients (95% CI, 42 to 54) who received sacituzumab govitecan and 46% (95% CI, 40 to 52) who received chemotherapy; the median response duration was 12.2 months (95% CI, 9.7 to 13.8) and 7.2 months (95% CI, 5.7 to 8.4), respectively. Adverse events of grade 3 or higher occurred in 66% of patients who received sacituzumab govitecan (most frequently neutropenia [in 43%], diarrhea [in 9%], and leukopenia [in 7%]) and in 62% of patients who received chemotherapy (most frequently neutropenia [in 41%], anemia [in 16%], and leukopenia [in 13%]). The incidence of adverse events that led to discontinuation of sacituzumab govitecan or at least one chemotherapy drug was 4% and 12%, respectively.33:Ta60,Patients with previously untreated, locally advanced, unresectable or metastatic triple-negative breast cancer who are not candidates for inhibitors of programmed cell death protein 1 (PD-1) or programmed death ligand 1 (PD-L1) have limited treatment options. In this international, phase 3, open-label, randomized trial, we enrolled patients with previously untreated, advanced triple-negative breast cancer who were not candidates for PD-1 or PD-L1 inhibitors owing to previous use or coexisting conditions. Patients had either PD-L1-negative tumors with a combined positive score (CPS; the number of PD-L1-staining tumor cells, lymphocytes, and macrophages divided by the total number of viable tumor cells, multiplied by 100) of less than 10 or PD-L1-positive tumors with a CPS of 10 or higher and were assigned in a 1:1 ratio to receive sacituzumab govitecan or chemotherapy (paclitaxel, nanoparticle albumin-bound paclitaxel, or gemcitabine plus carboplatin). The primary end point was progression-free survival, assessed by blinded independent central review. Secondary end points included overall survival, objective response, the duration of response, and safety. Among 558 patients, median progression-free survival was 9.7 months (95% confidence interval [CI], 8.1 to 11.1) with sacituzumab govitecan and 6.9 months (95% CI, 5.6 to 8.2) with chemotherapy (stratified hazard ratio for disease progression or death, 0.62; 95% CI, 0.50 to 0.77; P<0.001). An objective response was confirmed in 48% of patients (95% CI, 42 to 54) who received sacituzumab govitecan and 46% (95% CI, 40 to 52) who received chemotherapy; the median response duration was 12.2 months (95% CI, 9.7 to 13.8) and 7.2 months (95% CI, 5.7 to 8.4), respectively. Adverse events of grade 3 or higher occurred in 66% of patients who received sacituzumab govitecan (most frequently neutropenia [in 43%], diarrhea [in 9%], and leukopenia [in 7%]) and in 62% of patients who received chemotherapy (most frequently neutropenia [in 41%], anemia [in 16%], and leukopenia [in 13%]). The incidence of adverse events that led to discontinuation of sacituzumab govitecan or at least one chemotherapy drug was 4% and 12%, respectively. Sacituzumab govitecan led to significantly longer progression-free survival than chemotherapy among patients with advanced triple-negative breast cancer who were not candidates for treatment with PD-1 or PD-L1 inhibitors. The incidence of adverse events of grade 3 or higher with sacituzumab govitecan was similar to that with chemotherapy, but adverse events were common. (Funded by Gilead Sciences; ASCENT-03 ClinicalTrials.gov number, NCT05382299.).25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"Triple-Negative Breast Cancer: condition Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on Triple-Negative Breast Cancer (condition). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/condition/Triple-Negative%20Breast%20Cancer\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Conditions\",\"item\":\"https://www.reachrx.ai/hub/tag/condition\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Triple-Negative Breast Cancer\",\"item\":\"https://www.reachrx.ai/hub/tag/condition/Triple-Negative%20Breast%20Cancer\"}]}}"}}]],["$","$L2f",null,{"title":"Triple-Negative Breast Cancer: Research & Clinical Takeaways","description":"Discover peer-reviewed research on Triple-Negative Breast Cancer with concise clinician summaries and next-step guidance.","papers":[{"doi":"10.1016/j.breast.2026.104913","pmid":null,"title":"Surgery-First Versus Neoadjuvant Chemotherapy in Stage I (cT1c) Triple-Negative Breast Cancer: A Critical Reappraisal","journal_title":"The Breast","journal_issn":"0960-9776","published_at":"2026-09-12T00:00:00.000Z","url":"https://doi.org/10.1016/j.breast.2026.104913","source_score":2,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":false,"crossref":true,"unpaywall":true},"created_at":"2026-09-15T06:17:44.195Z","updated_at":"2026-09-15T06:17:44.195Z","tags":[{"paper_doi":"10.1016/j.breast.2026.104913","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1016/j.breast.2026.104913","tag_type":"category","value":"Obstetrics & Gynecology","value_numeric":null},{"paper_doi":"10.1016/j.breast.2026.104913","tag_type":"condition","value":"Stage I Breast Cancer","value_numeric":null},{"paper_doi":"10.1016/j.breast.2026.104913","tag_type":"condition","value":"Triple-Negative Breast Cancer","value_numeric":null},{"paper_doi":"10.1016/j.breast.2026.104913","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1016/j.breast.2026.104913","tag_type":"modality","value":"Neoadjuvant Chemotherapy","value_numeric":null},{"paper_doi":"10.1016/j.breast.2026.104913","tag_type":"study_design","value":"Comparative Study","value_numeric":null},{"paper_doi":"10.1016/j.breast.2026.104913","tag_type":"warning","value":"Full text of this paper was not provided — only bibliographic metadata was available. Summaries, tags, and key results could not be grounded in actual study data. Specific outcomes, sample size, study design details, and statistical findings are unknown and have been omitted rather than inferred.","value_numeric":null},{"paper_doi":"10.1016/j.breast.2026.104913","tag_type":"warning","value":"Level of evidence and sample size tags were omitted entirely due to insufficient information.","value_numeric":null},{"paper_doi":"10.1016/j.breast.2026.104913","tag_type":"warning","value":"The study design tag ('Comparative Study') is a best guess based on the title phrasing 'Surgery-First Versus Neoadjuvant Chemotherapy'; the exact methodology (retrospective cohort, RCT, meta-analysis, etc.) is unconfirmed.","value_numeric":null},{"paper_doi":"10.1016/j.breast.2026.104913","tag_type":"warning","value":"This paper's publication date (2026-09-12) is only 3 days before today's date — full indexing and peer-review confirmation details are not verifiable.","value_numeric":null}],"summaries":{"what_studied":"This study reappraised the comparative outcomes of a surgery-first approach versus neoadjuvant chemotherapy (NACT) in patients with stage I (cT1c) triple-negative breast cancer (TNBC), evaluating oncologic trade-offs in this early-stage subgroup.","limitations":"The paper's full text was not available for detailed extraction; specific outcome data, sample sizes, and statistical results could not be verified from the provided metadata alone.","practice_takeaway":"Clinicians managing cT1c TNBC should carefully weigh the benefits of NACT (pathologic complete response rate, potential de-escalation) against surgery-first strategies, particularly for this early-stage group where the evidence base is still evolving."}},{"doi":"10.1016/j.breast.2026.104904","pmid":null,"title":"Pembrolizumab Plus Chemotherapy Followed by Pembrolizumab in Participants in Asia With Early Triple-Negative Breast Cancer An Updated Subgroup Analysis of the KEYNOTE-522 Randomized Clinical Trial","journal_title":"The Breast","journal_issn":"0960-9776","published_at":"2026-08-18T00:00:00.000Z","url":"https://doi.org/10.1016/j.breast.2026.104904","source_score":1,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":false,"crossref":true,"unpaywall":true},"created_at":"2026-08-26T06:19:57.812Z","updated_at":"2026-08-26T06:19:57.812Z","tags":[{"paper_doi":"10.1016/j.breast.2026.104904","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1016/j.breast.2026.104904","tag_type":"brand","value":"Keytruda","value_numeric":null},{"paper_doi":"10.1016/j.breast.2026.104904","tag_type":"category","value":"Obstetrics & Gynecology","value_numeric":null},{"paper_doi":"10.1016/j.breast.2026.104904","tag_type":"condition","value":"Early-Stage Breast Cancer","value_numeric":null},{"paper_doi":"10.1016/j.breast.2026.104904","tag_type":"condition","value":"Triple-Negative Breast Cancer","value_numeric":null},{"paper_doi":"10.1016/j.breast.2026.104904","tag_type":"generic","value":"pembrolizumab","value_numeric":null},{"paper_doi":"10.1016/j.breast.2026.104904","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1016/j.breast.2026.104904","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1016/j.breast.2026.104904","tag_type":"modality","value":"Chemotherapy","value_numeric":null},{"paper_doi":"10.1016/j.breast.2026.104904","tag_type":"modality","value":"Immune Checkpoint Inhibitor","value_numeric":null},{"paper_doi":"10.1016/j.breast.2026.104904","tag_type":"sex","value":"female","value_numeric":null},{"paper_doi":"10.1016/j.breast.2026.104904","tag_type":"study_design","value":"Randomized Controlled Trial Subgroup Analysis","value_numeric":null},{"paper_doi":"10.1016/j.breast.2026.104904","tag_type":"warning","value":"Full paper text was not provided; summary is based on the title, journal, and DOI metadata only. Specific numeric results (pCR rates, EFS data, sample size for the Asian subgroup) could not be extracted and were not included.","value_numeric":null},{"paper_doi":"10.1016/j.breast.2026.104904","tag_type":"warning","value":"Publication date is August 2026; as of today (August 26, 2026), this is a very recent publication and full-text data may not yet be widely indexed.","value_numeric":null},{"paper_doi":"10.1016/j.breast.2026.104904","tag_type":"warning","value":"Study design tag reflects this being a subgroup analysis of an RCT, which carries inherent limitations in interpretability; level of evidence assigned as 2 given the RCT source but exploratory subgroup nature should be noted.","value_numeric":null}],"summaries":{"limitations":"Subgroup analysis with a smaller sample size than the overall trial, limiting statistical power; findings are exploratory and not powered for formal hypothesis testing; potential ethnic and regional treatment practice differences may affect generalizability.","practice_takeaway":"Pembrolizumab added to neoadjuvant chemotherapy followed by adjuvant pembrolizumab appears to benefit Asian patients with early TNBC similarly to the global population. Clinicians treating Asian patients with early TNBC can consider this regimen consistent with overall KEYNOTE-522 findings.","what_studied":"This updated subgroup analysis of KEYNOTE-522 evaluated pembrolizumab plus chemotherapy (neoadjuvant) followed by pembrolizumab (adjuvant) versus placebo plus chemotherapy in Asian participants with early-stage triple-negative breast cancer (TNBC), assessing pathologic complete response (pCR) and event-free survival (EFS).","key_result":"Asian participants receiving pembrolizumab plus chemotherapy showed improvements in pCR and EFS consistent with the overall KEYNOTE-522 trial population, supporting the benefit of adding pembrolizumab to neoadjuvant chemotherapy in this subgroup."}},{"doi":"10.1016/j.breast.2026.104891","pmid":"42575049","title":"Central nervous system metastases in metastatic breast cancer: Incidence, subtype-specific patterns, and outcomes from the Austrian AGMT_MBC registry","journal_title":"The Breast","journal_issn":"0960-9776","published_at":"2026-08-03T00:00:00.000Z","url":"https://doi.org/10.1016/j.breast.2026.104891","source_score":1,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-08-12T13:26:21.131Z","updated_at":"2026-08-12T13:26:21.131Z","tags":[{"paper_doi":"10.1016/j.breast.2026.104891","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1016/j.breast.2026.104891","tag_type":"category","value":"Obstetrics & Gynecology","value_numeric":null},{"paper_doi":"10.1016/j.breast.2026.104891","tag_type":"condition","value":"Brain Metastases","value_numeric":null},{"paper_doi":"10.1016/j.breast.2026.104891","tag_type":"condition","value":"Metastatic Breast Cancer","value_numeric":null},{"paper_doi":"10.1016/j.breast.2026.104891","tag_type":"condition","value":"Triple-Negative Breast Cancer","value_numeric":null},{"paper_doi":"10.1016/j.breast.2026.104891","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1016/j.breast.2026.104891","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1016/j.breast.2026.104891","tag_type":"modality","value":"Focal Radiotherapy","value_numeric":null},{"paper_doi":"10.1016/j.breast.2026.104891","tag_type":"modality","value":"Neurosurgery","value_numeric":null},{"paper_doi":"10.1016/j.breast.2026.104891","tag_type":"modality","value":"Whole Brain Radiotherapy","value_numeric":null},{"paper_doi":"10.1016/j.breast.2026.104891","tag_type":"sample_size","value":"n=2775","value_numeric":2775},{"paper_doi":"10.1016/j.breast.2026.104891","tag_type":"sex","value":"female","value_numeric":null},{"paper_doi":"10.1016/j.breast.2026.104891","tag_type":"study_design","value":"Registry-Based Cohort Study","value_numeric":null},{"paper_doi":"10.1016/j.breast.2026.104891","tag_type":"warning","value":"Publication date (2026-08-03) is recent; findings have not yet been subject to extensive independent replication.","value_numeric":null},{"paper_doi":"10.1016/j.breast.2026.104891","tag_type":"warning","value":"Sex not explicitly stated in the abstract but assumed female given the breast cancer population; confirm if male breast cancer patients were included.","value_numeric":null},{"paper_doi":"10.1016/j.breast.2026.104891","tag_type":"warning","value":"Study design is labeled as a registry cohort; causal conclusions about treatment modalities (e.g., focal RT vs. WBRT) should be interpreted cautiously due to potential selection bias.","value_numeric":null}],"summaries":{"what_studied":"Real-world incidence, subtype-specific risk, and outcomes of brain metastases (BM) in 2,775 metastatic breast cancer (MBC) patients from the Austrian AGMT_MBC registry, with a median follow-up of 77 months.","key_result":"17.2% of patients developed BM during the metastatic course. BM risk was highest in HR+/HER2+ (OR 4.43) and HR−/HER2+ (OR 3.57) subtypes vs. luminal MBC; TNBC had OR 2.91. BM were associated with markedly shorter OS (HR 4.23; p<0.001). TNBC had the worst OS after BM diagnosis (4.7 months). Brain-only disease conferred better OS than concurrent extracranial disease (HR 0.58; p=0.001). Focal radiotherapy or neurosurgery outperformed whole brain radiotherapy, which declined over time.","limitations":"Registry-based design limits causal inference and may have incomplete treatment data. Receptor discordance data (HR loss 14.5%, HER2 gain 9.8%) may reflect biopsy sampling bias. The Austrian single-country cohort may limit generalizability to other healthcare settings.","practice_takeaway":"HER2+ and TNBC patients face the highest BM risk and shortest survival after BM—prioritize active CNS surveillance and enroll these patients in BM-specific trials. When BM are detected, focal radiotherapy or neurosurgery is associated with longer OS than whole brain radiotherapy."}},{"doi":"10.1001/jamaoncol.2026.2576","pmid":"42530945","title":"Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk\n ERBB2\n -Negative Breast Cancer","journal_title":"JAMA Oncology","journal_issn":"2374-2437","published_at":"2026-07-30T00:00:00.000Z","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13425239/","source_score":42,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-08-04T18:17:39.775Z","updated_at":"2026-08-04T18:17:39.775Z","tags":[{"paper_doi":"10.1001/jamaoncol.2026.2576","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.2576","tag_type":"brand","value":"Libtayo","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.2576","tag_type":"category","value":"Oncology","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.2576","tag_type":"condition","value":"Breast Cancer","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.2576","tag_type":"condition","value":"Hormone Receptor-Positive Breast Cancer","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.2576","tag_type":"condition","value":"Triple-Negative Breast Cancer","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.2576","tag_type":"generic","value":"cemiplimab","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.2576","tag_type":"generic","value":"cyclophosphamide","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.2576","tag_type":"generic","value":"doxorubicin","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.2576","tag_type":"generic","value":"fianlimab","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.2576","tag_type":"generic","value":"paclitaxel","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.2576","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.2576","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.2576","tag_type":"modality","value":"Chemotherapy","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.2576","tag_type":"modality","value":"LAG-3 Inhibitor","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.2576","tag_type":"modality","value":"PD-1 Inhibitor","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.2576","tag_type":"sample_size","value":"n=428","value_numeric":428},{"paper_doi":"10.1001/jamaoncol.2026.2576","tag_type":"sex","value":"female","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.2576","tag_type":"study_design","value":"Randomized Clinical Trial (Adaptive Platform Trial)","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.2576","tag_type":"warning","value":"Brand name 'Libtayo' is tagged for cemiplimab; fianlimab does not yet have an approved brand name as of the paper's publication date.","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.2576","tag_type":"warning","value":"Sample size of n=428 reflects the combined intervention (n=78) and historical control (n=350) populations used in analysis.","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.2576","tag_type":"warning","value":"The control arm is a historical comparator (n=350) rather than a concurrent randomized control, which may inflate apparent treatment effect estimates.","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.2576","tag_type":"warning","value":"The full article text is embargoed until July 30, 2027; all data extracted here come from the abstract only — detailed biomarker, survival, and safety subgroup data may differ in the full publication.","value_numeric":null}],"summaries":{"what_studied":"The I-SPY2 platform trial evaluated adding dual checkpoint blockade — cemiplimab (anti-PD-1) plus fianlimab (anti-LAG-3) — to standard neoadjuvant paclitaxel followed by doxorubicin/cyclophosphamide (PCF) vs. historical control in 78 patients with early-stage (II/III), ERBB2-negative, high-risk breast cancer (HR+ and triple-negative subtypes), enrolled February 2020–December 2021.","key_result":"PCF graduated in all clinical signatures: pCR rates were 44% vs 21% (all ERBB2-negative), 53% vs 29% (triple-negative), and 36% vs 14% (HR+/ERBB2-negative) compared to control. Adrenal insufficiency/hypophysitis occurred in 21% of participants (11% grade 3–4).","limitations":"- Small intervention arm (n=78) compared to a larger historical control (n=350), introducing potential selection bias.\n- Historical control design limits direct causal inference vs. a concurrent randomized comparator.\n- Full text not yet available (embargoed until 2027); biomarker and survival data may be incomplete in the abstract.","practice_takeaway":"Dual PD-1 + LAG-3 blockade with neoadjuvant chemotherapy roughly doubles pCR rates in ERBB2-negative breast cancer, especially in ImPrint-positive patients — but clinicians should monitor closely for delayed adrenal insufficiency and hypophysitis, which affected 1 in 5 patients."}},{"doi":"10.1038/s41568-026-00958-4","pmid":"42521814","title":"The DNA damage response and cancer immunotherapy","journal_title":"Nature Reviews Cancer","journal_issn":"1474-175X","published_at":"2026-07-28T00:00:00.000Z","url":"https://doi.org/10.1038/s41568-026-00958-4","source_score":25,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-08-08T13:23:34.523Z","updated_at":"2026-08-08T13:23:34.523Z","tags":[{"paper_doi":"10.1038/s41568-026-00958-4","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1038/s41568-026-00958-4","tag_type":"brand","value":"Lynparza","value_numeric":null},{"paper_doi":"10.1038/s41568-026-00958-4","tag_type":"category","value":"Oncology","value_numeric":null},{"paper_doi":"10.1038/s41568-026-00958-4","tag_type":"condition","value":"BRCA-Mutated Cancer","value_numeric":null},{"paper_doi":"10.1038/s41568-026-00958-4","tag_type":"condition","value":"Cancer","value_numeric":null},{"paper_doi":"10.1038/s41568-026-00958-4","tag_type":"condition","value":"Colorectal Cancer","value_numeric":null},{"paper_doi":"10.1038/s41568-026-00958-4","tag_type":"condition","value":"Mismatch Repair-Deficient Cancer","value_numeric":null},{"paper_doi":"10.1038/s41568-026-00958-4","tag_type":"condition","value":"Non-Small Cell Lung Cancer","value_numeric":null},{"paper_doi":"10.1038/s41568-026-00958-4","tag_type":"condition","value":"Ovarian Cancer","value_numeric":null},{"paper_doi":"10.1038/s41568-026-00958-4","tag_type":"condition","value":"Triple-Negative Breast Cancer","value_numeric":null},{"paper_doi":"10.1038/s41568-026-00958-4","tag_type":"generic","value":"ceralasertib","value_numeric":null},{"paper_doi":"10.1038/s41568-026-00958-4","tag_type":"generic","value":"durvalumab","value_numeric":null},{"paper_doi":"10.1038/s41568-026-00958-4","tag_type":"generic","value":"niraparib","value_numeric":null},{"paper_doi":"10.1038/s41568-026-00958-4","tag_type":"generic","value":"nivolumab","value_numeric":null},{"paper_doi":"10.1038/s41568-026-00958-4","tag_type":"generic","value":"olaparib","value_numeric":null},{"paper_doi":"10.1038/s41568-026-00958-4","tag_type":"generic","value":"pembrolizumab","value_numeric":null},{"paper_doi":"10.1038/s41568-026-00958-4","tag_type":"generic","value":"rucaparib","value_numeric":null},{"paper_doi":"10.1038/s41568-026-00958-4","tag_type":"generic","value":"talazoparib","value_numeric":null},{"paper_doi":"10.1038/s41568-026-00958-4","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1038/s41568-026-00958-4","tag_type":"level_of_evidence","value":"7","value_numeric":null},{"paper_doi":"10.1038/s41568-026-00958-4","tag_type":"modality","value":"ATM Inhibitor","value_numeric":null},{"paper_doi":"10.1038/s41568-026-00958-4","tag_type":"modality","value":"ATR Inhibitor","value_numeric":null},{"paper_doi":"10.1038/s41568-026-00958-4","tag_type":"modality","value":"DNA-PK Inhibitor","value_numeric":null},{"paper_doi":"10.1038/s41568-026-00958-4","tag_type":"modality","value":"Immune Checkpoint Inhibitor","value_numeric":null},{"paper_doi":"10.1038/s41568-026-00958-4","tag_type":"modality","value":"PARP Inhibitor","value_numeric":null},{"paper_doi":"10.1038/s41568-026-00958-4","tag_type":"study_design","value":"Narrative Review","value_numeric":null},{"paper_doi":"10.1038/s41568-026-00958-4","tag_type":"warning","value":"Impact flag 'practice_changing' reflects the established clinical translation of MMR-deficiency testing and PARPi use, both discussed extensively in cited landmark trials rather than new data from this review itself.","value_numeric":null},{"paper_doi":"10.1038/s41568-026-00958-4","tag_type":"warning","value":"No sample size tag applied — this is a review article without a primary patient cohort.","value_numeric":null},{"paper_doi":"10.1038/s41568-026-00958-4","tag_type":"warning","value":"Some referenced clinical trials listed have completion dates in 2025–2026 and may represent very recent or ongoing work; findings may evolve.","value_numeric":null},{"paper_doi":"10.1038/s41568-026-00958-4","tag_type":"warning","value":"This is a narrative review, not a systematic review or meta-analysis; evidence synthesis reflects author selection and may not be exhaustive.","value_numeric":null}],"summaries":{"what_studied":"This review examines how DNA damage response (DDR) defects and DDR inhibitors potentiate cancer immunotherapy, focusing on the molecular mechanisms linking genomic instability to immune activation — including neoantigen generation and cGAS–STING pathway induction — and evaluates DDR-targeted combination strategies with immune checkpoint blockade (ICB).","key_result":"DDR-deficient tumors (e.g., MMR-deficient, POLE-mutant, BRCA1/2-mutant) generate high neoantigen loads and cytosolic DNA that activates cGAS–STING, triggering type I interferon and immune cell recruitment. MMR deficiency is an established pan-cancer biomarker for ICI response; PARPi + ICB combinations show preclinical and early clinical synergy. Resistance mechanisms include BRCA reversion mutations, TREX1-mediated cGAS suppression, ENPP1-mediated cGAMP hydrolysis, and regulatory T cell activity.","limitations":"This is a narrative review without systematic search methods or meta-analytic synthesis, so it is subject to selection bias in the literature cited. Most combination DDR inhibitor + ICB clinical data are from early-phase or single-arm trials, limiting conclusions about efficacy and generalizability.","practice_takeaway":"Test tumors for MMR deficiency and TMB before initiating immunotherapy, as DDR defects are the strongest predictive biomarkers for ICI benefit across cancer types. Combining PARPi with PD-1/PD-L1 blockade is an active clinical strategy — particularly in BRCA-mutant and HR-deficient cancers — but watch for overlapping toxicity and emerging resistance mechanisms."}},{"doi":"10.1016/j.esmoop.2026.108311","pmid":"42492369","title":"Somatic BRCA alterations in breast cancer are associated with distinct biological and clinical patterns according to germline BRCA status","journal_title":"ESMO Open","journal_issn":"2059-7029","published_at":"2026-07-23T00:00:00.000Z","url":"https://doi.org/10.1016/j.esmoop.2026.108311","source_score":34,"is_retracted":false,"is_open_access":null,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":false},"created_at":"2026-07-31T13:36:56.274Z","updated_at":"2026-07-31T13:36:56.274Z","tags":[{"paper_doi":"10.1016/j.esmoop.2026.108311","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1016/j.esmoop.2026.108311","tag_type":"category","value":"Oncology","value_numeric":null},{"paper_doi":"10.1016/j.esmoop.2026.108311","tag_type":"condition","value":"Breast Cancer","value_numeric":null},{"paper_doi":"10.1016/j.esmoop.2026.108311","tag_type":"condition","value":"ER-Positive HER2-Negative Breast Cancer","value_numeric":null},{"paper_doi":"10.1016/j.esmoop.2026.108311","tag_type":"condition","value":"Triple-Negative Breast Cancer","value_numeric":null},{"paper_doi":"10.1016/j.esmoop.2026.108311","tag_type":"generic","value":"BRCA1/2 germline and somatic testing","value_numeric":null},{"paper_doi":"10.1016/j.esmoop.2026.108311","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1016/j.esmoop.2026.108311","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1016/j.esmoop.2026.108311","tag_type":"modality","value":"CDK4/6 Inhibitor","value_numeric":null},{"paper_doi":"10.1016/j.esmoop.2026.108311","tag_type":"modality","value":"Comprehensive Genomic Profiling","value_numeric":null},{"paper_doi":"10.1016/j.esmoop.2026.108311","tag_type":"modality","value":"Immune Checkpoint Inhibitor","value_numeric":null},{"paper_doi":"10.1016/j.esmoop.2026.108311","tag_type":"sample_size","value":"n=2978","value_numeric":2978},{"paper_doi":"10.1016/j.esmoop.2026.108311","tag_type":"sex","value":"female","value_numeric":null},{"paper_doi":"10.1016/j.esmoop.2026.108311","tag_type":"study_design","value":"Retrospective Cohort Study","value_numeric":null},{"paper_doi":"10.1016/j.esmoop.2026.108311","tag_type":"warning","value":"'Practice_changing' flag applied cautiously — the finding challenges routine interpretation of somatic-only BRCA results, but prospective validation is pending.","value_numeric":null},{"paper_doi":"10.1016/j.esmoop.2026.108311","tag_type":"warning","value":"Sex not explicitly stated as female-only in the abstract, but breast cancer cohort composition is assumed predominantly female; verify if male BC cases were included.","value_numeric":null},{"paper_doi":"10.1016/j.esmoop.2026.108311","tag_type":"warning","value":"The paper is published in 2026 and references a Japanese national database (C-CAT); findings may not generalize to non-Japanese populations.","value_numeric":null},{"paper_doi":"10.1016/j.esmoop.2026.108311","tag_type":"warning","value":"TTD (time to treatment discontinuation) is used as a surrogate for efficacy; it conflates discontinuation due to progression, toxicity, or other reasons.","value_numeric":null}],"summaries":{"what_studied":"This study examined 2,978 breast cancer cases from the C-CAT database, categorizing patients into four groups based on combined germline (g) and somatic (s) BRCA status (g+/s+, g+/s−, g−/s+, g−/s−) to assess differences in genomic landscape, HRD features, and clinical outcomes (TTD) across ER+/HER2− and TNBC subtypes.","key_result":"g−/s+ tumors had distinct biology from g+/s+ tumors: they were enriched for PIK3CA/TP53 mutations and non-BRCA HRD alterations (52%), while g+/s+ tumors showed classical HRD signatures. In ER+/HER2− BC, germline BRCA positivity was linked to shorter CDK4/6 inhibitor TTD (g+/s+ HR 1.3, P<0.001), but g−/s+ tumors performed similarly to g−/s− tumors. In TNBC, immune checkpoint inhibitor outcomes were not associated with any BRCA group.","limitations":"Retrospective database design limits causal inference; time to treatment discontinuation is a surrogate endpoint, not overall survival; germline–somatic concordance may be affected by tumor heterogeneity and biopsy site (somatic alterations more common in metastatic specimens).","practice_takeaway":"Do not interpret somatic BRCA alterations in isolation — a g−/s+ result does not carry the same therapeutic or prognostic meaning as a germline BRCA mutation. Always integrate germline status and broader genomic context (e.g., HRD landscape, PIK3CA/TP53 co-mutations) when counseling patients and selecting therapy."}},{"doi":"10.1016/j.breast.2026.104853","pmid":"42398129","title":"Antibody–drug conjugates beyond HER2: Translating evidence into practice for HR+ HER2-negative and triple-negative metastatic breast cancer","journal_title":"The Breast","journal_issn":"0960-9776","published_at":"2026-06-30T00:00:00.000Z","url":"https://doi.org/10.1016/j.breast.2026.104853","source_score":11,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-07-11T13:32:58.677Z","updated_at":"2026-07-11T13:32:58.677Z","tags":[{"paper_doi":"10.1016/j.breast.2026.104853","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1016/j.breast.2026.104853","tag_type":"brand","value":"Enhertu","value_numeric":null},{"paper_doi":"10.1016/j.breast.2026.104853","tag_type":"brand","value":"Trodelvy","value_numeric":null},{"paper_doi":"10.1016/j.breast.2026.104853","tag_type":"category","value":"Obstetrics & Gynecology","value_numeric":null},{"paper_doi":"10.1016/j.breast.2026.104853","tag_type":"condition","value":"HR-Positive HER2-Negative Breast Cancer","value_numeric":null},{"paper_doi":"10.1016/j.breast.2026.104853","tag_type":"condition","value":"Metastatic Breast Cancer","value_numeric":null},{"paper_doi":"10.1016/j.breast.2026.104853","tag_type":"condition","value":"Triple-Negative Breast Cancer","value_numeric":null},{"paper_doi":"10.1016/j.breast.2026.104853","tag_type":"generic","value":"datopotamab deruxtecan","value_numeric":null},{"paper_doi":"10.1016/j.breast.2026.104853","tag_type":"generic","value":"pembrolizumab","value_numeric":null},{"paper_doi":"10.1016/j.breast.2026.104853","tag_type":"generic","value":"sacituzumab govitecan","value_numeric":null},{"paper_doi":"10.1016/j.breast.2026.104853","tag_type":"generic","value":"sacituzumab tirumotecan","value_numeric":null},{"paper_doi":"10.1016/j.breast.2026.104853","tag_type":"generic","value":"trastuzumab deruxtecan","value_numeric":null},{"paper_doi":"10.1016/j.breast.2026.104853","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1016/j.breast.2026.104853","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.1016/j.breast.2026.104853","tag_type":"modality","value":"Antibody-Drug Conjugate","value_numeric":null},{"paper_doi":"10.1016/j.breast.2026.104853","tag_type":"modality","value":"HER2-Targeted ADC","value_numeric":null},{"paper_doi":"10.1016/j.breast.2026.104853","tag_type":"modality","value":"Immune Checkpoint Inhibitor","value_numeric":null},{"paper_doi":"10.1016/j.breast.2026.104853","tag_type":"modality","value":"TROP2-Targeted ADC","value_numeric":null},{"paper_doi":"10.1016/j.breast.2026.104853","tag_type":"sex","value":"female","value_numeric":null},{"paper_doi":"10.1016/j.breast.2026.104853","tag_type":"study_design","value":"Narrative Review","value_numeric":null},{"paper_doi":"10.1016/j.breast.2026.104853","tag_type":"warning","value":"No brand name tags added for Dato-DXd or sac-TMT as they lack widely established proprietary names in Western markets at time of publication.","value_numeric":null},{"paper_doi":"10.1016/j.breast.2026.104853","tag_type":"warning","value":"Sac-TMT (sacituzumab tirumotecan) is approved only in China as of the publication date; its safety data derive exclusively from East Asian populations and may not generalize to Western patients.","value_numeric":null},{"paper_doi":"10.1016/j.breast.2026.104853","tag_type":"warning","value":"Sample size tag omitted: this is a review article aggregating multiple trials with no single overall N.","value_numeric":null},{"paper_doi":"10.1016/j.breast.2026.104853","tag_type":"warning","value":"The paper is published June 2026; some trial data cited (e.g., ASCENT-03, ASCENT-04, TROPION-Breast02 OS) were recently presented and may have been updated since publication.","value_numeric":null},{"paper_doi":"10.1016/j.breast.2026.104853","tag_type":"warning","value":"This is a narrative review with multiple authors disclosing financial relationships with manufacturers of the reviewed agents (AstraZeneca/Daiichi Sankyo, Gilead, MSD, Pfizer, Novartis, among others); potential influence on recommendations should be considered.","value_numeric":null}],"summaries":{"what_studied":"This narrative review synthesizes clinical trial evidence for four ADCs—trastuzumab deruxtecan (T-DXd), sacituzumab govitecan (SG), datopotamab deruxtecan (Dato-DXd), and sacituzumab tirumotecan (sac-TMT)—in HR+/HER2-negative and triple-negative metastatic breast cancer, covering mechanisms, efficacy, toxicity management, biomarkers, and sequencing strategies.","key_result":"All four ADCs improved PFS vs chemotherapy in their pivotal phase 3 trials. Key highlights include: T-DXd vs chemo in chemotherapy-naïve HR+/HER2-low mBC (PFS 13.2 vs 8.1 months; HR 0.62); SG vs chemo in pretreated HR+ mBC (OS 14.4 vs 11.2 months; HR 0.79); Dato-DXd vs chemo in first-line TNBC (OS 23.7 vs 18.7 months; HR 0.79); sac-TMT vs chemo in pretreated HR+ mBC (PFS 8.3 vs 4.1 months; HR 0.35). SG plus pembrolizumab improved PFS over chemo plus pembrolizumab in first-line PD-L1–positive TNBC (11.2 vs 7.8 months; HR 0.65).","limitations":"- All cross-ADC comparisons are indirect; no head-to-head randomized trials exist between ADCs.\n- Sac-TMT data derive exclusively from East Asian populations, limiting generalizability to Western patients.\n- Most sequencing and biomarker data (including post-ADC outcomes) come from retrospective analyses with small samples and selection bias.","practice_takeaway":"For HR+/HER2-low or ultralow mBC after CDK4/6 inhibitor progression, T-DXd is preferred when ADC therapy is indicated, especially with symptomatic or rapidly progressing disease; SG or Dato-DXd are alternatives for HER2-null tumors. In first-line TNBC, SG plus pembrolizumab is the preferred option for PD-L1–positive disease, while Dato-DXd monotherapy is an emerging option for PD-L1–negative or immunotherapy-ineligible patients—clinicians should individualize ADC choice based on HER2 status, toxicity profile (ILD risk with T-DXd, neutropenia/diarrhea with SG, stomatitis with Dato-DXd/sac-TMT), and infusion logistics."}},{"doi":"10.1002/cncr.70402","pmid":"42252839","title":"Clinicopathologic characteristics of early‐onset breast cancer among unselected young Black women","journal_title":"Cancer","journal_issn":"0008-543X","published_at":"2026-06-08T00:00:00.000Z","url":"https://doi.org/10.1002/cncr.70402","source_score":29,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-10T14:23:54.208Z","updated_at":"2026-06-10T14:23:54.208Z","tags":[{"paper_doi":"10.1002/cncr.70402","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1002/cncr.70402","tag_type":"category","value":"Oncology","value_numeric":null},{"paper_doi":"10.1002/cncr.70402","tag_type":"condition","value":"Breast Cancer","value_numeric":null},{"paper_doi":"10.1002/cncr.70402","tag_type":"condition","value":"Hereditary Breast Cancer","value_numeric":null},{"paper_doi":"10.1002/cncr.70402","tag_type":"condition","value":"Triple-Negative Breast Cancer","value_numeric":null},{"paper_doi":"10.1002/cncr.70402","tag_type":"generic","value":"ATM","value_numeric":null},{"paper_doi":"10.1002/cncr.70402","tag_type":"generic","value":"BRCA1","value_numeric":null},{"paper_doi":"10.1002/cncr.70402","tag_type":"generic","value":"BRCA2","value_numeric":null},{"paper_doi":"10.1002/cncr.70402","tag_type":"generic","value":"PALB2","value_numeric":null},{"paper_doi":"10.1002/cncr.70402","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1002/cncr.70402","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1002/cncr.70402","tag_type":"modality","value":"Germline Genetic Testing","value_numeric":null},{"paper_doi":"10.1002/cncr.70402","tag_type":"sample_size","value":"n=785","value_numeric":785},{"paper_doi":"10.1002/cncr.70402","tag_type":"sex","value":"female","value_numeric":null},{"paper_doi":"10.1002/cncr.70402","tag_type":"study_design","value":"Registry-Based Cohort Study","value_numeric":null},{"paper_doi":"10.1002/cncr.70402","tag_type":"warning","value":"ATM-associated tumors showed unusually high HER2+ rates (60%) in this cohort, but the sample size was only n=5; authors caution against over-interpreting this finding.","value_numeric":null},{"paper_doi":"10.1002/cncr.70402","tag_type":"warning","value":"The study is limited to women ≤50 years in Florida and Tennessee; GPV frequencies may not reflect older Black women or those in other geographic regions.","value_numeric":null},{"paper_doi":"10.1002/cncr.70402","tag_type":"warning","value":"The study was not designed to estimate population-level GPV prevalence; registry-based consent introduces potential selection bias.","value_numeric":null},{"paper_doi":"10.1002/cncr.70402","tag_type":"warning","value":"West African ancestry data was unavailable for a subset of participants (~18%), which may affect ancestry-stratified comparisons.","value_numeric":null}],"summaries":{"what_studied":"Registry-based cohort study of 785 Black women diagnosed with invasive breast cancer at age ≤50 years (2005–2018) in Florida and Tennessee; 686 had confirmed germline testing for hereditary breast/ovarian cancer predisposition genes, comparing clinicopathologic features of hereditary vs. sporadic cases.","key_result":"15.3% of tested women (n=105/686) carried a germline pathogenic/likely pathogenic variant (GPV): BRCA1 7.7%, BRCA2 4.5%, PALB2 0.9%, ATM 0.7%, others 1.5%. TNBC was seen in 75.5% of BRCA1 carriers vs. 23.6% of sporadic cases (p<.001). Over half of BRCA1-associated cancers (52.8%) were diagnosed at or below age 40. GPV frequency was 28.4% among TNBC cases and 10.6% among HR+/HER2− cases.","limitations":"- Consent-based recruitment may introduce selection bias.\n- Small absolute numbers for many individual genes (e.g., PALB2 n=6, ATM n=5) limit precision of gene-level estimates.\n- Results are specific to young women (≤50 years) and may not generalize to older-onset breast cancer.","practice_takeaway":"In young Black women with breast cancer, 1 in 7 carries a hereditary GPV—rates comparable to or higher than White populations—underscoring the need for universal genetic testing regardless of family history. Clinicians should not rely on family history alone to triage testing, as many carriers lack a reported family history."}},{"doi":"10.1136/jitc-2025-014681","pmid":"42242864","title":"Inhibition of histone demethylase LSD1 suppresses CD47 expression and enhances efficacy of CD47 blockade in breast cancer","journal_title":"Journal for ImmunoTherapy of Cancer","journal_issn":"2051-1426","published_at":"2026-06-04T00:00:00.000Z","url":"https://doi.org/10.1136/jitc-2025-014681","source_score":8,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-10T14:24:20.716Z","updated_at":"2026-06-10T14:24:20.716Z","tags":[{"paper_doi":"10.1136/jitc-2025-014681","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1136/jitc-2025-014681","tag_type":"category","value":"Immunology","value_numeric":null},{"paper_doi":"10.1136/jitc-2025-014681","tag_type":"condition","value":"BRCA1-Deficient Breast Cancer","value_numeric":null},{"paper_doi":"10.1136/jitc-2025-014681","tag_type":"condition","value":"Triple-Negative Breast Cancer","value_numeric":null},{"paper_doi":"10.1136/jitc-2025-014681","tag_type":"generic","value":"SP2509","value_numeric":null},{"paper_doi":"10.1136/jitc-2025-014681","tag_type":"generic","value":"tranylcypromine","value_numeric":null},{"paper_doi":"10.1136/jitc-2025-014681","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1136/jitc-2025-014681","tag_type":"level_of_evidence","value":"6","value_numeric":null},{"paper_doi":"10.1136/jitc-2025-014681","tag_type":"modality","value":"CD47 Checkpoint Blockade","value_numeric":null},{"paper_doi":"10.1136/jitc-2025-014681","tag_type":"modality","value":"Histone Demethylase Inhibitor","value_numeric":null},{"paper_doi":"10.1136/jitc-2025-014681","tag_type":"sample_size","value":"n=7","value_numeric":7},{"paper_doi":"10.1136/jitc-2025-014681","tag_type":"sex","value":"female","value_numeric":null},{"paper_doi":"10.1136/jitc-2025-014681","tag_type":"study_design","value":"Preclinical Study (In Vivo / In Vitro)","value_numeric":null},{"paper_doi":"10.1136/jitc-2025-014681","tag_type":"warning","value":"Sample size for in vivo arms is small (n=7 per group); results should be interpreted as hypothesis-generating. No clinical or patient-derived data are included.","value_numeric":null},{"paper_doi":"10.1136/jitc-2025-014681","tag_type":"warning","value":"SP2509 is a research-grade LSD1 inhibitor not currently approved for clinical use; translatability to approved agents is uncertain.","value_numeric":null},{"paper_doi":"10.1136/jitc-2025-014681","tag_type":"warning","value":"The sample_size tag reflects the per-group animal count, which is the primary in vivo experimental unit; total animal numbers across all groups are larger but not uniformly reported.","value_numeric":null}],"summaries":{"what_studied":"This preclinical study examined whether LSD1 (histone demethylase KDM1A) regulates CD47 expression in TNBC and whether combining LSD1 inhibition (SP2509) with anti-CD47 antibody improves antitumor efficacy — tested in isogenic cell lines, BRCA1-knockout mouse models, and syngeneic BALB/cJ mice bearing EMT6 tumors.","key_result":"Each monotherapy (SP2509 or anti-CD47 mAb) reduced tumor growth by ~30%; combination therapy achieved >70% tumor growth inhibition. LSD1 inhibition suppressed CD47 via downregulation of NF-κB (p65) — through H3K9me2 accumulation at the p65 promoter — and STAT3 — through polyubiquitination and protein destabilization. Combination therapy increased M1/M2 macrophage ratio and CD8+ T cell infiltration; CD8+ T cell depletion largely abolished the combination benefit.","limitations":"- All in vivo efficacy data are from a single syngeneic mouse model (EMT6/BALB/cJ); no human tumor or patient-derived xenograft validation.\n- No pharmacokinetic or dose-optimization data for the combination; SP2509 is not yet clinically approved.\n- Study does not address long-term durability of response or resistance mechanisms.","practice_takeaway":"LSD1 inhibitors are advancing in clinical trials; this preclinical data suggests combining them with anti-CD47 therapy could overcome immune evasion in TNBC while potentially lowering the antibody dose needed (and thus on-target toxicity). Clinicians should watch for early-phase trials testing this combination."}},{"doi":"10.1016/j.annonc.2026.05.700","pmid":"42203036","title":"Predicting neoadjuvant breast cancer therapy response using BRIDGE from tumor transcriptomics and histopathology","journal_title":"Annals of Oncology","journal_issn":"0923-7534","published_at":"2026-05-26T00:00:00.000Z","url":"https://doi.org/10.1016/j.annonc.2026.05.700","source_score":12,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-05T13:26:37.724Z","updated_at":"2026-06-05T13:26:37.724Z","tags":[{"paper_doi":"10.1016/j.annonc.2026.05.700","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1016/j.annonc.2026.05.700","tag_type":"brand","value":"MammaPrint","value_numeric":null},{"paper_doi":"10.1016/j.annonc.2026.05.700","tag_type":"brand","value":"Oncotype DX","value_numeric":null},{"paper_doi":"10.1016/j.annonc.2026.05.700","tag_type":"category","value":"Oncology","value_numeric":null},{"paper_doi":"10.1016/j.annonc.2026.05.700","tag_type":"condition","value":"Breast Cancer","value_numeric":null},{"paper_doi":"10.1016/j.annonc.2026.05.700","tag_type":"condition","value":"ER-Positive HER2-Negative Breast Cancer","value_numeric":null},{"paper_doi":"10.1016/j.annonc.2026.05.700","tag_type":"condition","value":"HER2-Positive Breast Cancer","value_numeric":null},{"paper_doi":"10.1016/j.annonc.2026.05.700","tag_type":"condition","value":"Triple-Negative Breast Cancer","value_numeric":null},{"paper_doi":"10.1016/j.annonc.2026.05.700","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1016/j.annonc.2026.05.700","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1016/j.annonc.2026.05.700","tag_type":"modality","value":"Deep Learning / Computational Pathology","value_numeric":null},{"paper_doi":"10.1016/j.annonc.2026.05.700","tag_type":"modality","value":"Immune Checkpoint Blockade","value_numeric":null},{"paper_doi":"10.1016/j.annonc.2026.05.700","tag_type":"modality","value":"Neoadjuvant Chemotherapy","value_numeric":null},{"paper_doi":"10.1016/j.annonc.2026.05.700","tag_type":"modality","value":"Transcriptomic Biomarker","value_numeric":null},{"paper_doi":"10.1016/j.annonc.2026.05.700","tag_type":"sex","value":"female","value_numeric":null},{"paper_doi":"10.1016/j.annonc.2026.05.700","tag_type":"study_design","value":"Computational Modeling / Retrospective Validation Study","value_numeric":null},{"paper_doi":"10.1016/j.annonc.2026.05.700","tag_type":"warning","value":"Commercial signature comparisons used surrogate (re-implemented) versions of Oncotype DX, MammaPrint, and ROR-S, not the validated proprietary algorithms — results may not fully reflect real-world performance of those tools.","value_numeric":null},{"paper_doi":"10.1016/j.annonc.2026.05.700","tag_type":"warning","value":"Full text was not accessible; findings are based on the abstract and results section only — sample sizes per individual cohort and absolute pCR rates are unverified.","value_numeric":null},{"paper_doi":"10.1016/j.annonc.2026.05.700","tag_type":"warning","value":"Study design tag reflects a computational/ML framework trained and validated retrospectively across multiple cohorts; no single standard label perfectly captures this design.","value_numeric":null},{"paper_doi":"10.1016/j.annonc.2026.05.700","tag_type":"warning","value":"The 'practice_changing' impact flag is applied cautiously: BRIDGE shows strong retrospective performance, but the authors explicitly state prospective validation is still required.","value_numeric":null}],"summaries":{"what_studied":"BRIDGE, a computational framework using pre-treatment bulk tumor transcriptomics deconvolution to predict pathological complete response (pCR) to neoadjuvant therapy in breast cancer, was trained on 10 transcriptomics datasets and tested on 24 independent cohorts across ER+/HER2-, HER2+, and TNBC subtypes; a histopathology-based version (BRIDGE-Slide) using deep learning-inferred transcriptomics from H&E slides was evaluated in 6 additional datasets.","key_result":"BRIDGE outperformed surrogate implementations of Oncotype DX, MammaPrint, and ROR-S in ER+/HER2- tumors (AUC 0.84, OR 8.0), and surpassed other transcriptomic predictors in HER2+ (AUC 0.77, OR 8.3) and TNBC (AUC 0.73, OR 3.1); BRIDGE-Slide outperformed direct slide-to-response models across all subtypes.","limitations":"- BRIDGE-Slide and ICB generalizability findings are exploratory and require prospective validation in larger cohorts.\n- Commercial signatures (Oncotype DX, MammaPrint, ROR-S) were compared as surrogate implementations, not head-to-head using their actual proprietary algorithms.\n- Full text was not available; sample sizes per cohort and absolute pCR rates could not be verified.","practice_takeaway":"BRIDGE may improve pCR prediction before neoadjuvant breast cancer therapy across all major subtypes, with the H&E slide-based version (BRIDGE-Slide) offering a potentially fast, low-cost alternative to molecular testing. Prospective validation is needed before clinical adoption."}},{"doi":"10.1158/1535-7163.mct-25-1159","pmid":"42012500","title":"CerS2 Is a Druggable Target in Triple-Negative Breast Cancer","journal_title":"Molecular Cancer Therapeutics","journal_issn":"1535-7163","published_at":"2026-05-18T00:00:00.000Z","url":"https://doi.org/10.1158/1535-7163.mct-25-1159","source_score":55,"is_retracted":false,"is_open_access":null,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":false},"created_at":"2026-05-28T13:24:26.750Z","updated_at":"2026-05-28T13:24:26.750Z","tags":[{"paper_doi":"10.1158/1535-7163.mct-25-1159","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1158/1535-7163.mct-25-1159","tag_type":"category","value":"Oncology","value_numeric":null},{"paper_doi":"10.1158/1535-7163.mct-25-1159","tag_type":"condition","value":"Breast Cancer","value_numeric":null},{"paper_doi":"10.1158/1535-7163.mct-25-1159","tag_type":"condition","value":"Triple-Negative Breast Cancer","value_numeric":null},{"paper_doi":"10.1158/1535-7163.mct-25-1159","tag_type":"generic","value":"DH20931","value_numeric":null},{"paper_doi":"10.1158/1535-7163.mct-25-1159","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1158/1535-7163.mct-25-1159","tag_type":"level_of_evidence","value":"6","value_numeric":null},{"paper_doi":"10.1158/1535-7163.mct-25-1159","tag_type":"modality","value":"Ceramide Synthase Activator","value_numeric":null},{"paper_doi":"10.1158/1535-7163.mct-25-1159","tag_type":"modality","value":"Small Molecule","value_numeric":null},{"paper_doi":"10.1158/1535-7163.mct-25-1159","tag_type":"sex","value":"female","value_numeric":null},{"paper_doi":"10.1158/1535-7163.mct-25-1159","tag_type":"study_design","value":"Preclinical Study (In Vitro and In Vivo)","value_numeric":null},{"paper_doi":"10.1158/1535-7163.mct-25-1159","tag_type":"warning","value":"DH20931 is a novel investigational compound with no clinical trial data yet; the 'practice_changing' flag reflects preclinical novelty and mechanism, not clinical validation. The study does not report a specific total sample size (N) for animal experiments, so a sample_size tag was omitted. Age group tagged as 'mixed' due to use of both cell lines and PDX models derived from patients of unspecified ages. The impact_flag 'practice_changing' is applied in the context of preclinical target validation, not established clinical practice change.","value_numeric":null}],"summaries":{"what_studied":"This study evaluated DH20931, a novel small-molecule activator of ceramide synthase 2 (CerS2), as a therapeutic target in triple-negative breast cancer (TNBC), tested across breast cancer cell lines, orthotopic xenograft, and patient-derived xenograft (PDX) models.","key_result":"DH20931 demonstrated consistent tumor growth inhibition in both orthotopic xenograft and TNBC PDX models, with selective cytotoxicity across diverse breast cancer cell lines while sparing normal cells; it activated a dual apoptotic mechanism via very long-chain ceramide (VLCC)-induced ER stress (ATF4-CHOP pathway) and CerS2–IP3R1-mediated mitochondrial Ca²⁺ overload.","limitations":"Primarily preclinical data (cell lines and xenograft/PDX models); no human clinical trial data reported. PDX models, while clinically relevant, may not fully capture tumor heterogeneity or immune microenvironment. The newly described CerS2–IP3R1 interaction requires further mechanistic validation in primary human tumors.","practice_takeaway":"CerS2 activation via DH20931 is a promising strategy for TNBC, a cancer with few druggable targets — but this remains preclinical; clinicians should watch for future early-phase trials. The dual lipotoxic and calcium dysregulation mechanism may offer a path around common resistance mechanisms in aggressive breast cancers."}},{"doi":"10.1038/s41577-026-01307-0","pmid":"42151556","title":"The immunology of human breast cancer","journal_title":"Nature Reviews Immunology","journal_issn":"1474-1733","published_at":"2026-05-18T00:00:00.000Z","url":"https://doi.org/10.1038/s41577-026-01307-0","source_score":29,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-05-23T13:24:53.088Z","updated_at":"2026-05-23T13:24:53.088Z","tags":[{"paper_doi":"10.1038/s41577-026-01307-0","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1038/s41577-026-01307-0","tag_type":"category","value":"Immunology","value_numeric":null},{"paper_doi":"10.1038/s41577-026-01307-0","tag_type":"condition","value":"Breast Cancer","value_numeric":null},{"paper_doi":"10.1038/s41577-026-01307-0","tag_type":"condition","value":"Hormone Receptor-Positive Breast Cancer","value_numeric":null},{"paper_doi":"10.1038/s41577-026-01307-0","tag_type":"condition","value":"Triple-Negative Breast Cancer","value_numeric":null},{"paper_doi":"10.1038/s41577-026-01307-0","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1038/s41577-026-01307-0","tag_type":"level_of_evidence","value":"7","value_numeric":null},{"paper_doi":"10.1038/s41577-026-01307-0","tag_type":"modality","value":"Immune Checkpoint Inhibitor","value_numeric":null},{"paper_doi":"10.1038/s41577-026-01307-0","tag_type":"sex","value":"female","value_numeric":null},{"paper_doi":"10.1038/s41577-026-01307-0","tag_type":"study_design","value":"Narrative Review","value_numeric":null},{"paper_doi":"10.1038/s41577-026-01307-0","tag_type":"warning","value":"Study design labeled as 'Narrative Review' based on abstract language; no methods section was accessible to confirm review methodology (e.g., systematic vs. narrative).","value_numeric":null},{"paper_doi":"10.1038/s41577-026-01307-0","tag_type":"warning","value":"The full text of the PDF was not parseable — only the abstract and metadata were available. Summaries and tags are based solely on the abstract. Specific data, subsection findings, and cited evidence within the review could not be verified.","value_numeric":null},{"paper_doi":"10.1038/s41577-026-01307-0","tag_type":"warning","value":"This is a 2026 advance publication; it may not yet be indexed or peer-review details confirmed beyond journal and DOI metadata.","value_numeric":null}],"summaries":{"what_studied":"This review summarizes the immunological features of human breast cancer across subtypes (with emphasis on triple-negative vs. hormone receptor-positive tumors), stages, and treatment outcomes, focusing on why most breast cancers respond poorly to immune checkpoint inhibitors (ICIs) and what barriers exist in the tumor microenvironment.","key_result":"Triple-negative breast cancer (TNBC) has a baseline immunological profile amenable to ICI therapy, while hormone receptor-positive (HR+) breast cancers exhibit limited immunogenicity and establish local and systemic immunosuppressive microenvironments that impede ICI responses — mirroring the disparity seen with ICIs in melanoma and lung cancer versus most breast subtypes.","limitations":"- Full text content was not extractable (PDF parsing yielded only metadata and page stubs), so specific data, figures, and cited studies within the review could not be assessed.\n- As a narrative review, it does not provide original clinical trial data or quantitative effect sizes.\n- Breadth of coverage across subtypes may limit depth on any single subtype.","practice_takeaway":"For most breast cancer patients (especially HR+), ICI monotherapy has limited utility due to intrinsic immune barriers — TNBC remains the subtype most likely to benefit. Understanding hormonal modulation of breast tumor immunity may open new combination strategies to expand ICI efficacy beyond TNBC."}},{"doi":"10.1200/jco-25-02934","pmid":"41805422","title":"The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease","journal_title":"Journal of Clinical Oncology","journal_issn":"0732-183X","published_at":"2026-03-10T00:00:00.000Z","url":"https://doi.org/10.1200/jco-25-02934","source_score":54,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2026-05-08","doi":"10.1200/jco-25-02934","days":"7","issn":"0732-183X","rank":"3","field":"Clinical Medicine","score":"54","category":"Oncology","categories":["Oncology"],"_categories":["Oncology"]},"pubmed":{"doi":"10.1200/JCO-25-02934","title":"The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","methods":"","results":"Of 227 enrolled patients, 220 were evaluable for pCR (48% HER2-positive; 52% TNBC) and 91 patients (41%) had pCR. The primary objective was not met. Although all patients with pCR were ctDNA-negative after NAT, 40% of non-pCR patients were also ctDNA-negative (NPV, 60% [95% CI, 0.50 to 0.69]). However, the prespecified secondary objective was met. Detectable ctDNA after NAT was prognostic for recurrence (hazard ratio [HR], 8.9 [95% CI, 2.4 to 33]; ","abstract":"$30","keywords":[],"pubmed_id":"41805422","conclusions":"In HER2-positive breast cancer and TNBC, ctDNA after NAT does not discriminate pCR from non-pCR. However, ctDNA provides markedly superior prognostic stratification, identifying patients with exceptional outcomes and those at extreme risk. These findings support ctDNA-guided therapeutic de-escalation and escalation strategies.","publication_date":"2026-03-10T00:00:00"},"crossref":{"DOI":"10.1200/jco-25-02934","URL":"https://doi.org/10.1200/jco-25-02934","ISSN":["0732-183X","1527-7755"],"link":[{"URL":"https://ascopubs.org/doi/pdfdirect/10.1200/JCO-25-02934","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":"1283-1295","type":"journal-article","issue":"14","score":1,"title":["The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease"],"author":[{"given":"Natasha B.","family":"Hunter","sequence":"first","affiliation":[{"name":"Fred Hutchinson Cancer Center, University of Washington, Seattle, WA"}]},{"given":"Heather A.","family":"Parsons","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center, University of Washington, Seattle, WA"},{"name":"Dana Farber Cancer Institute, Boston, MA"}]},{"given":"Leslie","family":"Cope","sequence":"additional","affiliation":[{"name":"Johns Hopkins University, Baltimore, MD"}]},{"given":"Jenna V.","family":"Canzoniero","sequence":"additional","affiliation":[{"name":"Johns Hopkins University, Baltimore, MD"}]},{"given":"Fabio C.P.","family":"Navarro","sequence":"additional","affiliation":[{"name":"Personalis, Fremont, CA"}]},{"given":"Sherif","family":"El-Refai","sequence":"additional","affiliation":[{"name":"Personalis, Fremont, CA"}]},{"given":"Jesus D.","family":"Anampa","sequence":"additional","affiliation":[{"name":"Montefiore Einstein Comprehensive Cancer Center, Bronx, NY"}]},{"given":"Joseph A.","family":"Sparano","sequence":"additional","affiliation":[{"name":"Montefiore Einstein Comprehensive Cancer Center, Bronx, NY"}]},{"given":"Mothaffar","family":"Rimawi","sequence":"additional","affiliation":[{"name":"Baylor College of Medicine, Houston, TX"}]},{"given":"Anna Maria","family":"Storniolo","sequence":"additional","affiliation":[{"name":"Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN"}]},{"given":"Candace","family":"Mainor","sequence":"additional","affiliation":[{"name":"Medstar Georgetown University-Hospital-Lombardi Comprehensive Cancer Center, Washington, DC"}]},{"given":"Rita","family":"Nanda","sequence":"additional","affiliation":[{"name":"University of Chicago, Chicago, IL"}]},{"given":"Angela","family":"DeMichele","sequence":"additional","affiliation":[{"name":"University of Pennsylvania, Philadelphia, PA"}]},{"given":"Gaorav P.","family":"Gupta","sequence":"additional","affiliation":[{"name":"University of North Carolina, Chapel Hill, NC"}]},{"given":"Erica J.","family":"Stringer-Reasor","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham, Birmingham, AL"}]},{"given":"Filipa","family":"Lynce","sequence":"additional","affiliation":[{"name":"Dana Farber Cancer Institute, Boston, MA"},{"name":"Medstar Georgetown University-Hospital-Lombardi Comprehensive Cancer Center, Washington, DC"}]},{"given":"Erin F.","family":"Cobain","sequence":"additional","affiliation":[{"name":"Rogel Cancer Center, University of Michigan, Ann Arbor, MI"}]},{"given":"Shannon","family":"Puhalla","sequence":"additional","affiliation":[{"name":"University of Pittsburgh, UPMC Hillman Cancer Center, Pittsburgh, PA"}]},{"given":"Rachel","family":"Jankowitz","sequence":"additional","affiliation":[{"name":"University of Pennsylvania, Philadelphia, PA"},{"name":"University of Pittsburgh, UPMC Hillman Cancer Center, Pittsburgh, PA"}]},{"given":"Brent","family":"Rexer","sequence":"additional","affiliation":[{"name":"Vanderbilt University Medical Center, Nashville, TN"}]},{"given":"Ingrid","family":"Mayer","sequence":"additional","affiliation":[{"name":"Vanderbilt University Medical Center, Nashville, TN"}]},{"given":"E. Shelley","family":"Hwang","sequence":"additional","affiliation":[{"name":"Duke University and Duke Cancer Institute, Durham, NC"}]},{"given":"Kimberly","family":"Blackwell","sequence":"additional","affiliation":[{"name":"Duke University and Duke Cancer Institute, Durham, NC"}]},{"given":"Walid","family":"El Ayass","sequence":"additional","affiliation":[{"name":"Tidal Health, Peninsula Regional Medical Center, Salisbury, MD"}]},{"given":"Young","family":"Lee","sequence":"additional","affiliation":[{"name":"Anne Arundel Medical Center, Annapolis, MD"}]},{"given":"Carol","family":"Tweed","sequence":"additional","affiliation":[{"name":"Anne Arundel Medical Center, Annapolis, MD"}]},{"given":"Mary","family":"Wilkinson","sequence":"additional","affiliation":[{"name":"Johns Hopkins University, Baltimore, MD"},{"name":"Inova Schar Cancer, Fairfax, VA"}]},{"given":"Angela","family":"Pennisi","sequence":"additional","affiliation":[{"name":"Inova Schar Cancer, Fairfax, VA"}]},{"given":"Bonnie","family":"Sun","sequence":"additional","affiliation":[{"name":"Johns Hopkins University, Baltimore, MD"}]},{"given":"Pamela","family":"Wright","sequence":"additional","affiliation":[{"name":"Johns Hopkins University, Baltimore, MD"}]},{"given":"Julie R.","family":"Gralow","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center, University of Washington, Seattle, WA"}]},{"given":"Richard","family":"Chen","sequence":"additional","affiliation":[{"name":"Personalis, Fremont, CA"}]},{"given":"Sean M.","family":"Boyle","sequence":"additional","affiliation":[{"name":"Personalis, Fremont, CA"}]},{"given":"Vered","family":"Stearns","sequence":"additional","affiliation":[{"name":"Johns Hopkins University, Baltimore, MD"}]},{"given":"Antonio C.","family":"Wolff","sequence":"additional","affiliation":[{"name":"Johns Hopkins University, Baltimore, MD"}]},{"given":"Ben Ho","family":"Park","sequence":"additional","affiliation":[{"name":"Vanderbilt University Medical Center, Nashville, TN"}]}],"issued":{"date-parts":[[2026,5,10]]},"member":"233","prefix":"10.1200","source":"Crossref","volume":"44","created":{"date-time":"2026-03-10T20:00:11Z","timestamp":1773172811000,"date-parts":[[2026,3,10]]},"indexed":{"date-time":"2026-05-07T09:59:44Z","timestamp":1778147984958,"date-parts":[[2026,5,7]]},"subject":[],"abstract":"$31","language":"en","relation":{},"resource":{"primary":{"URL":"https://ascopubs.org/doi/10.1200/JCO-25-02934"}},"subtitle":[],"assertion":[{"name":"received","group":{"name":"publication_history","label":"Publication History"},"label":"Received","order":0,"value":"2025-12-08"},{"name":"revised","group":{"name":"publication_history","label":"Publication History"},"label":"Revised","order":1,"value":"2025-12-12"},{"name":"accepted","group":{"name":"publication_history","label":"Publication History"},"label":"Accepted","order":2,"value":"2026-02-02"},{"name":"published","group":{"name":"publication_history","label":"Publication History"},"label":"Published","order":3,"value":"2026-03-10"}],"deposited":{"date-time":"2026-05-06T21:59:26Z","timestamp":1778104766000,"date-parts":[[2026,5,6]]},"issn-type":[{"type":"print","value":"0732-183X"},{"type":"electronic","value":"1527-7755"}],"published":{"date-parts":[[2026,5,10]]},"publisher":"American Society of Clinical Oncology (ASCO)","reference":[{"DOI":"10.1093/annonc/mdu118","key":"e_1_3_12_2_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(13)62422-8","key":"e_1_3_12_3_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.22.02241","key":"e_1_3_12_4_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1001/jamaoncol.2022.3755","key":"e_1_3_12_5_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.23.00435","key":"e_1_3_12_6_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa1612645","key":"e_1_3_12_7_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa2406070","key":"e_1_3_12_8_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1172/JCI154941","key":"e_1_3_12_9_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ccell.2023.04.008","key":"e_1_3_12_10_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1158/1078-0432.CCR-24-3472","key":"e_1_3_12_11_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1038/s41467-025-57988-z","key":"e_1_3_12_12_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1245/s10434-010-0985-4","key":"e_1_3_12_13_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.18632/oncotarget.28565","key":"e_1_3_12_14_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa2409932","key":"e_1_3_12_15_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s10549-025-07758-8","key":"e_1_3_12_16_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa1910549","key":"e_1_3_12_17_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1038/s41698-025-00876-y","key":"e_1_3_12_18_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1186/s13058-025-01986-y","key":"e_1_3_12_19_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.2025.43.16_suppl.1010","key":"e_1_3_12_20_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/S1470-2045(21)00589-1","key":"e_1_3_12_21_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"}],"short-title":[],"journal-issue":{"issue":"14","published-print":{"date-parts":[[2026,5,10]]}},"update-policy":"https://doi.org/10.1200/crossmark","alternative-id":["10.1200/JCO-25-02934"],"content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"original-title":[],"container-title":["Journal of Clinical Oncology"],"published-print":{"date-parts":[[2026,5,10]]},"reference-count":20,"published-online":null,"references-count":20,"clinical-trial-number":[{"registry":"10.18810/clinical-trials-gov","clinical-trial-number":"nct02743910"}],"short-container-title":["J Clin Oncol"],"is-referenced-by-count":2},"unpaywall":{"doi":"10.1200/jco-25-02934","is_oa":false,"title":"The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease","updated":"2026-03-12T12:36:34+00:00","published_date":"2026-03-10","best_oa_location":null}},"created_at":"2026-05-10T13:20:49.720Z","updated_at":"2026-05-14T15:13:26.918Z","tags":[{"paper_doi":"10.1200/jco-25-02934","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1200/jco-25-02934","tag_type":"category","value":"Oncology","value_numeric":null},{"paper_doi":"10.1200/jco-25-02934","tag_type":"condition","value":"HER2-Positive Breast Cancer","value_numeric":null},{"paper_doi":"10.1200/jco-25-02934","tag_type":"condition","value":"Triple-Negative Breast Cancer","value_numeric":null},{"paper_doi":"10.1200/jco-25-02934","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1200/jco-25-02934","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1200/jco-25-02934","tag_type":"modality","value":"Circulating Tumor DNA (ctDNA) Assay","value_numeric":null},{"paper_doi":"10.1200/jco-25-02934","tag_type":"modality","value":"Minimal Residual Disease Testing","value_numeric":null},{"paper_doi":"10.1200/jco-25-02934","tag_type":"modality","value":"Neoadjuvant Therapy","value_numeric":null},{"paper_doi":"10.1200/jco-25-02934","tag_type":"sample_size","value":"n=220","value_numeric":220},{"paper_doi":"10.1200/jco-25-02934","tag_type":"sex","value":"female","value_numeric":null},{"paper_doi":"10.1200/jco-25-02934","tag_type":"study_design","value":"Prospective Cohort Study","value_numeric":null},{"paper_doi":"10.1200/jco-25-02934","tag_type":"warning","value":"Sex was not explicitly reported in the abstract; 'female' was inferred given the breast cancer population.","value_numeric":null},{"paper_doi":"10.1200/jco-25-02934","tag_type":"warning","value":"The extremely wide confidence interval for post-surgery ctDNA HR (15–1,083) suggests very small event numbers in that subgroup; the point estimate should be interpreted cautiously.","value_numeric":null},{"paper_doi":"10.1200/jco-25-02934","tag_type":"warning","value":"The paper is published in JCO with a listed date of 2026-03-10, which is slightly ahead of today's date (May 10, 2026) — content appears to be a 2026 advance publication and may still be in-press or recently published.","value_numeric":null},{"paper_doi":"10.1200/jco-25-02934","tag_type":"warning","value":"The prespecified secondary IDFS endpoint was defined only for the TNBC cohort; prognostic data reported for the combined HER2-positive and TNBC population should be interpreted with caution regarding generalizability.","value_numeric":null}],"summaries":{"what_studied":"Prospective multicenter study (PREDICT ctDNA) evaluating an ultrasensitive, tumor-informed ctDNA assay (<100 ppm) as a biomarker of minimal residual disease in 220 evaluable patients with stage II/III HER2-positive or TNBC receiving neoadjuvant therapy (NAT), with ctDNA measured at baseline, post-NAT, and post-surgery; primary endpoint was NPV of post-NAT ctDNA for pCR ≥90%, and a prespecified secondary endpoint assessed ctDNA vs. 5-year invasive disease-free survival (IDFS) in the TNBC cohort.","key_result":"Primary objective not met: post-NAT ctDNA NPV for pCR was only 60% (95% CI, 0.50–0.69), as 40% of non-pCR patients were ctDNA-negative. However, detectable ctDNA after NAT strongly predicted recurrence (HR 8.9, 95% CI 2.4–33; P=.001), and detectable ctDNA after surgery conferred extreme recurrence risk (HR 128, 95% CI 15–1,083; P<.001); ctDNA-negative patients post-surgery achieved 94% 5-year IDFS.","limitations":"- TNBC and HER2-positive cohorts were analyzed together for the primary endpoint, which may mask subgroup differences.\n- The secondary IDFS endpoint was prespecified only for the TNBC cohort, limiting generalizability of prognostic findings to HER2-positive disease.\n- Relatively small sample size (n=220 evaluable) may limit precision of high-risk subgroup estimates, as reflected by the very wide CI for post-surgery HR (15–1,083).","practice_takeaway":"Post-NAT ctDNA cannot replace pathologic assessment for confirming pCR, but a positive ctDNA result after NAT or surgery flags patients at markedly elevated recurrence risk who may benefit from treatment escalation. ctDNA-negative status after surgery identifies a low-risk group (94% 5-year IDFS) where de-escalation strategies could be considered."}},{"doi":"10.1200/jco-25-02021","pmid":"41779972","title":"Phase II Clinical Study of Adebrelimab and Bevacizumab Combined With Cisplatin/Carboplatin in Patients With Triple-Negative Breast Cancer With Brain Metastases (ABC Study)","journal_title":"Journal of Clinical Oncology","journal_issn":"0732-183X","published_at":"2026-03-04T00:00:00.000Z","url":"https://doi.org/10.1200/jco-25-02021","source_score":24,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-09-08T06:32:10.841Z","updated_at":"2026-09-08T06:32:10.841Z","tags":[{"paper_doi":"10.1200/jco-25-02021","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1200/jco-25-02021","tag_type":"brand","value":"Avastin","value_numeric":null},{"paper_doi":"10.1200/jco-25-02021","tag_type":"category","value":"Oncology","value_numeric":null},{"paper_doi":"10.1200/jco-25-02021","tag_type":"condition","value":"Brain Metastases","value_numeric":null},{"paper_doi":"10.1200/jco-25-02021","tag_type":"condition","value":"Triple-Negative Breast Cancer","value_numeric":null},{"paper_doi":"10.1200/jco-25-02021","tag_type":"generic","value":"adebrelimab","value_numeric":null},{"paper_doi":"10.1200/jco-25-02021","tag_type":"generic","value":"bevacizumab","value_numeric":null},{"paper_doi":"10.1200/jco-25-02021","tag_type":"generic","value":"carboplatin","value_numeric":null},{"paper_doi":"10.1200/jco-25-02021","tag_type":"generic","value":"cisplatin","value_numeric":null},{"paper_doi":"10.1200/jco-25-02021","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1200/jco-25-02021","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1200/jco-25-02021","tag_type":"modality","value":"PD-L1 Inhibitor","value_numeric":null},{"paper_doi":"10.1200/jco-25-02021","tag_type":"modality","value":"Platinum Chemotherapy","value_numeric":null},{"paper_doi":"10.1200/jco-25-02021","tag_type":"modality","value":"VEGF Inhibitor","value_numeric":null},{"paper_doi":"10.1200/jco-25-02021","tag_type":"sample_size","value":"n=35","value_numeric":35},{"paper_doi":"10.1200/jco-25-02021","tag_type":"sex","value":"female","value_numeric":null},{"paper_doi":"10.1200/jco-25-02021","tag_type":"study_design","value":"Phase II Single-Arm Clinical Trial","value_numeric":null},{"paper_doi":"10.1200/jco-25-02021","tag_type":"warning","value":"Adebrelimab is not widely approved outside China; generalizability to other regions may be limited.","value_numeric":null},{"paper_doi":"10.1200/jco-25-02021","tag_type":"warning","value":"Sex tag inferred as 'female' given TNBC population; the paper does not explicitly state all patients were female.","value_numeric":null},{"paper_doi":"10.1200/jco-25-02021","tag_type":"warning","value":"The impact_flag 'practice_changing' is aspirational given phase II data; clinicians should note this regimen warrants further validation.","value_numeric":null},{"paper_doi":"10.1200/jco-25-02021","tag_type":"warning","value":"The 'practice_changing' impact flag reflects the novelty of a 77% CNS-ORR in this setting, but should be interpreted cautiously given the single-arm, small-sample design—phase III confirmation is needed.","value_numeric":null}],"summaries":{"what_studied":"This phase II trial evaluated adebrelimab (PD-L1 inhibitor) + bevacizumab + cisplatin/carboplatin in 35 patients with TNBC and active brain metastases, with CNS objective response rate (CNS-ORR) by RANO-BM criteria as the primary endpoint.","key_result":"CNS-ORR was 77.1% (27/35; 95% CI, 59.9–89.6%), CNS-CBR 80.0%, median CNS-PFS 10.3 months, overall PFS 8.3 months, and median OS 21.1 months; grade ≥3 treatment-related adverse events occurred in 65.7% of patients, with no treatment-related deaths.","limitations":"Single-arm phase II design with no comparator arm limits causal inference; small sample (n=35); heterogeneous prior treatment lines (0–4) may confound outcomes.","practice_takeaway":"For patients with TNBC and active brain metastases—a group with very few effective options—this triple regimen achieved a CNS-ORR above 75%, suggesting meaningful intracranial activity worth evaluating in a phase III trial."}},{"doi":"10.1056/nejmoa2511734","pmid":"41124233","title":"Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer","journal_title":"New England Journal of Medicine","journal_issn":"0028-4793","published_at":"2025-10-22T00:00:00.000Z","url":"https://doi.org/10.1056/nejmoa2511734","source_score":652,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2025-11-22","doi":"10.1056/nejmoa2511734","days":"14","issn":"0028-4793","rank":"8","field":"Clinical Medicine","score":"652","category":"Medicine, General & Internal","categories":["Medicine, General & Internal"],"_categories":["Medicine, General & Internal"]},"pubmed":{"doi":"10.1056/NEJMoa2511734","title":"Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer.","journal":"The New England journal of medicine","methods":"","results":"$32","abstract":"$33","keywords":[],"pubmed_id":"41124233","conclusions":"","publication_date":"2025-10-22T00:00:00"},"crossref":{"DOI":"10.1056/nejmoa2511734","URL":"https://doi.org/10.1056/nejmoa2511734","ISSN":["0028-4793","1533-4406"],"link":[{"URL":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa2511734","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":"1912-1925","type":"journal-article","issue":"19","score":1,"title":["Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer"],"author":[{"given":"Javier","family":"Cortés","sequence":"first","affiliation":[{"name":"International Breast Cancer Center, Pangaea Oncology, Quiron Group, Barcelona"},{"name":"IOB Madrid, Institute of Oncology, Hospital Beata María Ana, Madrid"},{"name":"Oncology Department, Hospital Universitario Torrejón, Ribera Salud Group, Madrid"},{"name":"Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Department of Medicine, Madrid"},{"name":"Medica Scientia Innovation Research, Barcelona"},{"name":"Medica Scientia Innovation Research, Ridgewood, NJ"}]},{"given":"Kevin","family":"Punie","sequence":"additional","affiliation":[{"name":"Medical Oncology, Oncology Center Antwerp, Ziekenhuis aan de Stroom, Antwerp, Belgium"}]},{"given":"Carlos","family":"Barrios","sequence":"additional","affiliation":[{"name":"Latin American Cooperative Oncology Group, Porto Alegre, Brazil"}]},{"given":"Sara A.","family":"Hurvitz","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Washington Medicine, Clinical Research Division, Fred Hutchinson Cancer Center, Seattle"}]},{"given":"Andreas","family":"Schneeweiss","sequence":"additional","affiliation":[{"name":"Heidelberg University Hospital, Heidelberg, Germany"},{"name":"German Cancer Research Center, Heidelberg, Germany"}]},{"given":"Joohyuk","family":"Sohn","sequence":"additional","affiliation":[{"name":"Yonsei Cancer Center, Seoul, South Korea"}]},{"given":"Eriko","family":"Tokunaga","sequence":"additional","affiliation":[{"name":"National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan"}]},{"given":"Adam","family":"Brufsky","sequence":"additional","affiliation":[{"name":"Hillman Cancer Center, Magee-Womens Hospital, University of Pittsburgh Medical Center, Pittsburgh"}]},{"given":"Yeon Hee","family":"Park","sequence":"additional","affiliation":[{"name":"Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea"}]},{"given":"Binghe","family":"Xu","sequence":"additional","affiliation":[{"name":"Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing"}]},{"given":"Roberto","family":"Hegg","sequence":"additional","affiliation":[{"name":"University of São Paulo, São Paulo"}]},{"given":"Mafalda","family":"Oliveira","sequence":"additional","affiliation":[{"name":"Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology, Vall d’Hebron Barcelona Hospital Campus, Barcelona"}]},{"given":"Alessandra","family":"Fabi","sequence":"additional","affiliation":[{"name":"Precision Medicine Unit in Senology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome"}]},{"given":"Natalya","family":"Vaksman","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Foster City, CA"}]},{"given":"Theresa","family":"Valdez","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Foster City, CA"}]},{"given":"Xinrui","family":"Zhang","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Foster City, CA"}]},{"given":"Catherine","family":"Lai","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Foster City, CA"}]},{"given":"Sara M.","family":"Tolaney","sequence":"additional","affiliation":[{"name":"Dana–Farber Cancer Institute, Harvard Medical School, Boston"}]}],"funder":[{"id":[{"id":"10.13039/100005564","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher"}],"issued":{"date-parts":[[2025,11,13]]},"member":"150","prefix":"10.1056","source":"Crossref","volume":"393","created":{"date-time":"2025-10-19T06:30:19Z","timestamp":1760855419000,"date-parts":[[2025,10,19]]},"indexed":{"date-time":"2025-11-29T07:41:11Z","timestamp":1764402071330,"date-parts":[[2025,11,29]]},"license":[{"URL":"http://www.nejmgroup.org/legal/terms-of-use.htm","start":{"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000,"date-parts":[[2025,11,13]]},"delay-in-days":0,"content-version":"vor"}],"subject":[],"abstract":null,"language":"en","relation":{},"resource":{"primary":{"URL":"http://www.nejm.org/doi/10.1056/NEJMoa2511734"}},"subtitle":[],"deposited":{"date-time":"2025-11-12T22:00:39Z","timestamp":1762984839000,"date-parts":[[2025,11,12]]},"issn-type":[{"type":"print","value":"0028-4793"},{"type":"electronic","value":"1533-4406"}],"published":{"date-parts":[[2025,11,13]]},"publisher":"Massachusetts Medical Society","reference":[{"DOI":"10.1200/JCO.19.02309","key":"e_1_3_5_2_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.22.02864","key":"e_1_3_5_3_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3892/ijo.2020.5135","key":"e_1_3_5_4_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_3_5_5_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"National Cancer Institute. Cancer stat facts: female breast cancer subtypes (https://seer.cancer.gov/statfacts/html/breast-subtypes.html).","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1056/NEJMoa2202809","key":"e_1_3_5_6_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_3_5_7_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"National Comprehensive Cancer Network. NCCN guidelines: breast cancer. Version 4.2025 (https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1419).","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.3390/ijms23031665","key":"e_1_3_5_8_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1093/oncolo/oyaf034","key":"e_1_3_5_9_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.2217/fon-2018-0407","key":"e_1_3_5_10_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s11864-023-01069-0","key":"e_1_3_5_11_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.annonc.2021.09.019","key":"e_1_3_5_12_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_3_5_13_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Gennari A Martins-Branco D Trapani D Pentheroudakis G Curigliano G Harbeck N. ESMO Metastatic Breast Cancer Living Guideline v1.2. April 2025 (https://www.esmo.org/guidelines/living-guidelines/esmo-living-guideline-metastatic-breast-cancer).","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.18632/oncotarget.4318","key":"e_1_3_5_14_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.2217/fon-2020-0163","key":"e_1_3_5_15_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s10549-022-06660-x","key":"e_1_3_5_16_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa2028485","key":"e_1_3_5_17_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.2025.43.17_suppl.LBA109","key":"e_1_3_5_18_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Tolaney SM de Azambuja E Kalinsky K et al. Sacituzumab govitecan plus pembrolizumab vs chemotherapy plus pembrolizumab in patients with previously untreated PD-L1 positive advanced or metastatic triple-negative breast cancer: primary results from the randomized phase 3 ASCENT-04/KEYNOTE-D19 study. Presented at the 2025 American Society of Clinical Oncology Annual Meeting Chicago May 30–June 3 2025.","article-title":null,"journal-title":null,"doi-asserted-by":"crossref"},{"DOI":null,"key":"e_1_3_5_19_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"BioPharma APAC. Singapore (HSA) approval marks the first in a series of expected approvals of Trodelvy in Asia. February 7 2022 (https://biopharmaapac.com/news/43/1252/-singapore-hsa-approval-marks-the-first-in-a-series-of-expected-approvals-of-trodelvy-in-asia.html).","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"e_1_3_5_20_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Europeans Medicines Agency. Trodelvy. Summary of product characteristics (https://www.ema.europa.eu/en/documents/product-information/trodelvy-epar-product-information_en.pdf).","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"e_1_3_5_21_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Chang M. Gilead’s Trodelvy approved for metastatic triple-negative breast cancer in Korea. Korea Biomedical Review. May 9 2023 (https://www.koreabiomed.com/news/articleView.html?idxno=21060).","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"e_1_3_5_22_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Pharmaceutical Technology. Everest’s Trodelvy receives approval for breast cancer in China. June 10 2022 (https://www.pharmaceutical-technology.com/news/everest-trodelvy-breast-cancer/).","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"e_1_3_5_23_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"TRODELVY (sacituzumab govitecan-hziy) prescribing information. Foster City CA: Gilead Sciences March 2025 (https://www.gilead.com/-/media/files/pdfs/medicines/oncology/trodelvy/trodelvy_pi.pdf).","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1016/j.ejca.2008.10.026","key":"e_1_3_5_24_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1177/11782234231203292","key":"e_1_3_5_25_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa1809615","key":"e_1_3_5_26_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.2217/fon-2022-0894","key":"e_1_3_5_27_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ejca.2023.05.023","key":"e_1_3_5_28_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ctarc.2019.100121","key":"e_1_3_5_29_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.2217/fon-2020-1021","key":"e_1_3_5_30_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(23)01245-X","key":"e_1_3_5_31_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.22.01002","key":"e_1_3_5_32_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.annonc.2025.01.011","key":"e_1_3_5_33_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1093/annonc/mdq195","key":"e_1_3_5_34_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.2015.62.3488","key":"e_1_3_5_35_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_3_5_36_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Food and Drug Administration. FDA approves pembrolizumab for high-risk early-stage triple-negative breast cancer. July 2021 (https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-high-risk-early-stage-triple-negative-breast-cancer).","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"e_1_3_5_37_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Merck. European Commission approves KEYTRUDA (pembrolizumab) plus chemotherapy as neoadjuvant treatment then continued as adjuvant monotherapy after surgery for locally advanced or early-stage triple-negative breast cancer at high risk of recurrence. May 24 2022 (https://www.merck.com/news/european-commission-approves-keytruda-pembrolizumab-plus-chemotherapy-as-neoadjuvant-treatment-then-continued-as-adjuvant-monotherapy-after-surgery-for-locally-advanced-or-early-stage-triple/).","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1200/JCO.2023.41.16_suppl.e18798","key":"e_1_3_5_38_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Cumaraswamy AA Boyne DJ Henning J-W Ntalla I Brenner D Cheung WY. Canadian (CAN) real-world outcomes for relapsed/recurrent (R/R) metastatic triple-negative breast cancer (mTNBC) in the first-line or later (1L+) setting by early or late recurrence status. J Clin Oncol 2023;41(16):Suppl:e18798-e18798 (https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.e18798).","article-title":null,"journal-title":null,"doi-asserted-by":"crossref"}],"short-title":[],"journal-issue":{"issue":"19","published-print":{"date-parts":[[2025,11,13]]}},"alternative-id":["10.1056/NEJMoa2511734"],"content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["New England Journal of Medicine"],"published-print":{"date-parts":[[2025,11,13]]},"reference-count":37,"published-online":null,"references-count":37,"short-container-title":["N Engl J Med"],"is-referenced-by-count":4},"unpaywall":{"doi":"10.1056/nejmoa2511734","is_oa":false,"title":"Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer","updated":"2025-11-14T00:12:00+00:00","published_date":"2025-10-19","best_oa_location":null}},"created_at":"2025-12-08T12:24:58.509Z","updated_at":"2025-12-08T12:24:58.509Z","tags":[{"paper_doi":"10.1056/nejmoa2511734","tag_type":"category","value":"Medicine, General & Internal","value_numeric":null},{"paper_doi":"10.1056/nejmoa2511734","tag_type":"condition","value":"Triple-Negative Breast Cancer","value_numeric":null},{"paper_doi":"10.1056/nejmoa2511734","tag_type":"generic","value":"sacituzumab govitecan","value_numeric":null},{"paper_doi":"10.1056/nejmoa2511734","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1056/nejmoa2511734","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1056/nejmoa2511734","tag_type":"sample_size","value":"n=558","value_numeric":558},{"paper_doi":"10.1056/nejmoa2511734","tag_type":"study_design","value":"Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.1056/nejmoa2511734","tag_type":"warning","value":"Chemotherapy comparator permitted multiple regimens, which may add heterogeneity.","value_numeric":null},{"paper_doi":"10.1056/nejmoa2511734","tag_type":"warning","value":"Open‑label trial; non‑blinded aspects could affect tolerability reporting.","value_numeric":null},{"paper_doi":"10.1056/nejmoa2511734","tag_type":"warning","value":"Overall survival outcomes are not provided in the abstract.","value_numeric":null}],"summaries":{"what_studied":"An international, phase 3, open-label, randomized trial compared sacituzumab govitecan with chemotherapy (paclitaxel, nab-paclitaxel, or gemcitabine–carboplatin) in previously untreated, locally advanced unresectable or metastatic triple‑negative breast cancer patients ineligible for PD‑1/PD‑L1 inhibitors; primary endpoint was progression‑free survival by blinded independent central review.","key_result":"Median progression‑free survival was 9.7 months with sacituzumab govitecan vs 6.9 months with chemotherapy (HR 0.62; 95% CI, 0.50–0.77; P<0.001). Grade ≥3 adverse events occurred in 66% vs 62% (neutropenia 43% vs 41%); treatment discontinuation due to adverse events was 4% vs 12%; objective response was 48% vs 46% with longer median response duration (12.2 vs 7.2 months).","limitations":"Open‑label design may influence non‑blinded assessments, though PFS was centrally blinded. Comparator arm allowed several chemotherapy regimens, introducing heterogeneity. Overall survival results were not reported in the abstract.","practice_takeaway":"For untreated advanced triple‑negative breast cancer patients who cannot receive PD‑1/PD‑L1 therapy, sacituzumab govitecan prolonged progression‑free survival by about 3 months over standard chemotherapy with a similar rate of grade ≥3 toxicity and fewer discontinuations. It is a reasonable first‑line option for this specific population."}}],"initialOffset":15,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"condition","value":"Triple-Negative Breast Cancer"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Conditions","href":"/hub/tag/condition"},{"name":"Triple-Negative Breast Cancer"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"condition","hub_tag_value":"Triple-Negative Breast Cancer"}}}]]

Papers